# Sunitinib + Docetaxel as Second-line Treatment in Gastric Cancer

> **NCT01238055** · PHASE2 · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 116 (actual)

## Conditions studied

- Advanced Gastric Cancer

## Interventions

- **DRUG:** Docetaxel + Sunitinib
- **DRUG:** Docetaxel only

## Key facts

- **NCT ID:** NCT01238055
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2012-04
- **Final completion:** 2012-10
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2013-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01238055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01238055, "Sunitinib + Docetaxel as Second-line Treatment in Gastric Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01238055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*